Transfer of all assets and liabilities of MorphoSys’ research and diagnostic antibody segment, the AbD Serotec, in addition to all shares of the subsidiaries MorphoSys UK Ltd., MorphoSys AbD GmbH and MorphoSys US, Inc. to Bio-Rad were completed.
MorphoSys chief financial officer Jens Holstein said the company reached the closing of the transaction just after a short time after the announcement was made.
"With the divestment of AbD Serotec completed, MorphoSys can devote 100% of its attention to building value in its core therapeutics business," Holstein added.